Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli

被引:69
作者
Marcusson, LL
Olofsson, SK
Lindgren, PK
Cars, O
Hughes, D
机构
[1] Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden
[2] Uppsala Univ, Dept Med Sci, S-75122 Uppsala, Sweden
关键词
MPC; UTI; E; coli; mutant selection window;
D O I
10.1093/jac/dki136
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To measure the mutant prevention concentration (MPC) of ciprofloxacin for a set of urinary tract infection (UTI) Escherichia coli isolates with different levels of susceptibility and determine whether MPC can be predicted from MIC. Methods: MPC was defined as the lowest ciprofloxacin concentration that prevented the growth of resistant colonies when 1010 bacteria were spread on solid medium and incubated for 96 h at 37 degrees C. MIC was measured by Etest. Bacteria surviving (persisting) at MPC were isolated and quantified from agar plugs taken after 96h. The genes hipA and hipB were amplified by PCR from persisters and sequenced. Results: Isolates with MICs above the NCCLS breakpoint for ciprofloxacin resistance (4 mg/L) typically have MPCs greater than 32mg/L. Isolates with MICs below the breakpoint for ciprofloxacin susceptibility (1 mg/L) have MPCs up to 5 mg/L. MPC/MIC is similar to 16 for most susceptible isolates but there are several notable exceptions (MPC/MIC > 100). Resistant colonies arising one dilution step below MPC often had MIC > MPC. In every case tested, a proportion of cells survived (persisted), but did not grow into colonies, at MPC, without any increase in MIC. Conclusions: MPCs were determined for all ciprofloxacin-susceptible isolates. MPC is not accurately predicted from MIC. Colonies selected below MPC frequently have MIC > MPC, suggesting multiple mutations. A small fraction of cells from all strains tested survived for 96 h at MPC, without any associated increase in MIC. These survivors/persisters are not hipAB mutants.
引用
收藏
页码:938 / 943
页数:6
相关论文
共 51 条
[1]   Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J].
Allen, GP ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2606-2614
[2]  
Baquero F, 1997, CIBA F SYMP, V207, P93
[3]  
Baquero F, 1997, J CHEMOTHERAPY, V9, P29
[4]  
BAQUERO F, 1990, EUR UROL, V17, P3
[5]  
BAQUERO F, 2001, CIBA FOUND S, V207, P105
[6]   The safety profile of the fluoroquinolones [J].
Bertino, J ;
Fish, D .
CLINICAL THERAPEUTICS, 2000, 22 (07) :798-817
[7]   Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].
Blondeau, JM ;
Zhao, XL ;
Hansen, G ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438
[8]   Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose [J].
Boy, D ;
Well, M ;
Kinzig-Schippers, M ;
Sörgel, F ;
Ankel-Fuchs, D ;
Naber, KG .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 :S6-S16
[9]   Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV [J].
Breines, DM ;
Ouabdesselam, S ;
Ng, EY ;
Tankovic, J ;
Shah, S ;
Soussy, CJ ;
Hooper, DC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :175-179
[10]   Rapid and simple determination of the Escherichia coli phylogenetic group [J].
Clermont, O ;
Bonacorsi, S ;
Bingen, E .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2000, 66 (10) :4555-4558